Copyright Seeking Alpha
Novanta targets $400M advanced surgery revenue by 2030 as new product launches accelerate growth Nov. 04, 2025 2:07 PM ETNovanta Inc. (NOVT) StockAI-Generated Earnings Calls Insights Comments Earnings Call Insights: Novanta Inc. (NOVT) Q3 2025 Management View CEO Matthijs Glastra stated that "Novanta delivered above expectations for the third quarter, beating our outlook for sales, margins and adjusted EPS." He highlighted record revenue of $248 million, a 3% sequential increase, with new product revenue growing Seeking Alpha's Disclaimer: The earnings call insights are compilations of earnings call transcripts and other content available on the Seeking Alpha website. The insights are generated by an AI tool and have not been curated or reviewed by editors. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of the earnings call insights cannot be guaranteed. Please see full earnings call transcripts here. The earnings call insights are intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Quick Insights Advanced Surgery, Robotics and Automation, and medical consumables are cited as primary growth drivers, with Advanced Surgery revenue projected to double by 2030 and medical consumables expected to grow double digits for the remainder of the decade. Management expects margin expansion through regional manufacturing hub consolidation, estimating 100 basis points improvement, and foresees cash flow recovering as tax and restructuring impacts wane. Risks include macroeconomic and trade challenges, especially tariffs, potential delays in customer adoption of emerging products, and ongoing volatility in the Precision Medicine business. Recommended For You More Trending News
